News

News Subscription

Feb 21. 2018
Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
Read more
Download
Jan 10. 2018
Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific
Read more
Download
Jan 03. 2018
Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
Read more
Download
Dec 21. 2017
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)
Read more
Download
Dec 01. 2017
Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
Read more
Download
Nov 02. 2017
Basilea reports on commercial progress of antifungal Cresemba® in Europe
Read more
Download
Oct 31. 2017
Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor
Read more
Download
Oct 23. 2017
Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
Read more
Download
Sep 28. 2017
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
Read more
Download
Sep 12. 2017
Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel
Read more
Download